WuXi Biologics to invest $1.4bn to expand CRDMO facility in Singapore

By NS Healthcare Staff Writer

20 Jul 22

The investment will strengthen WuXi Biologics’ global research, development and manufacturing network to meet the growing demand from…

PharmaceuticalsContract Manufacturing

WuXi Biologics expands Hangzhou facility to produce microbial-derived products

By NS Healthcare Staff Writer

05 Jul 22

WuXi Biologics said the expansion is in response to growing market demand and will enable it to provide…

PharmaceuticalsContract Manufacturing

Fujifilm to invest $1.6bn in FDB to boost cell culture manufacturing

By NS Healthcare Staff Writer

30 Jun 22

With the new investment, Fujifilm will add eight new 20,000L bioreactors at FDB’s manufacturing site in Hillerød, Denmark,…

PharmaceuticalsContract Manufacturing

Moderna to establish new mRNA manufacturing facility in Kenya

By NS Healthcare Staff Writer

08 Mar 22

The company has also announced its public health strategy, which targets the prevention of infectious diseases by advancing…

PharmaceuticalsContract Manufacturing

Fujifilm to buy Atara’s cell therapy facility to expand CDMO business

By NS Healthcare Staff Writer

27 Jan 22

The 90,000ft² manufacturing facility, Atara T-cell Operations and Manufacturing (ATOM), supports clinical and commercial cell therapy manufacturing and…

PharmaceuticalsContract Manufacturing

Novavax extends manufacturing agreement with South Korea’s SK bioscience

By NS Healthcare Staff Writer

24 Dec 21

Under the expanded agreement, SK bioscience will reserve additional manufacturing capacity to produce antigen, a key component of…

PharmaceuticalsContract Manufacturing

PCI to acquire lyophilisation services provider LSNE

By NS Healthcare Staff Writer

13 Oct 21

The transaction, which marks PCI’s fourth acquisition in the past three years, enables the company to obtain five…

PharmaceuticalsContract Manufacturing

Fujifilm to transfer radiopharmaceutical business to PeptiDream

By NS Healthcare Staff Writer

03 Sep 21

Fujifilm Toyama Chemical’s radiopharmaceutical business will be succeeded by a new entity, formed through an absorption-type split

PharmaceuticalsContract Manufacturing

Fujifilm to invest additional $850m in FDB to expand capacity for biologics

By NS Healthcare Staff Writer

30 Jun 21

The investment will expand FDB’s capacity for recombinant vaccines and advanced gene therapies in the US and the…

PharmaceuticalsContract Manufacturing

Humanigen, Chime sign manufacturing deal for Covid-19 drug candidate lenzilumab

By NS Healthcare Staff Writer

17 May 21

Under the agreement, Chime Biologics will produce lenzilumab bulk drug substance and drug product for Humanigen for commercial…

PharmaceuticalsContract Manufacturing